Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers C > Headlines for Cytokinetics, Inc. > News item |
Cytokinetics reiterated by JMP at market outperform
Cytokinetics Inc was reiterated by JMP Securities analyst Charles Duncan at a market outperform rating with a price target on the stock of $13 per share following its taking the lead research role on SB-921 in hematologic cancers from partner GlaxoSmithKline plc. Cytokinetics shares Wednesday were down $0.46, or 5.46%, at $7.96 on volume of 305,347 shares versus the three-month running average of 126,026 shares.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.